BioInvent International (BINV) Q3 2025 earnings summary

Executive summary

• Strategic portfolio prioritization and refocus in Q3 2025 to accelerate lead programs BI-1206 and BI-1808, pausing early-stage assets for near- to mid-term value creation.

• Initiation of pivotal Phase 2a trial for BI-1206 in first-line NSCLC and uveal melanoma, and continued progress for BI-1808 in CTCL.

• Board changes with Vincent Ossipow stepping down after nearly a decade.

• Updated clinical data for BT-001 presented at ESMO 2025, showing positive antitumoral activity and ongoing investigator-led trials.

• Accelerated clinical progress and earlier-than-expected data readouts due to strong recruitment and interest.

Financial highlights

• Net sales for Jan–Sep 2025 reached SEK 223 million, mainly from a USD 20 million royalty rights sale to XOMA, up from SEK 23 million in 2024.

• Q3 2025 net sales were SEK 3.3 million, down from SEK 12.8 million in Q3 2024.

• Operating costs for Jan–Sep 2025 totaled SEK 446 million, reflecting higher R&D and personnel expenses.

• Loss after tax for Jan–Sep 2025 was SEK -207.1 million, improving from SEK -312.5 million year-over-year.

• Liquid funds and investments at period end were SEK 690 million, with financing secured into Q1 2027.

Outlook and guidance

• Multiple data updates for BI-1808 and BI-1206 expected in 2025, including Phase 2a monotherapy and combination data.

• First data from BI-1206 first-line solid tumor trial anticipated in H2 2026.

• Cost base expected to decrease slightly in 2026 following recent cost-cutting measures.

• Focus on advancing pivotal studies and potential partnering opportunities as data matures.